MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER I)
1 other identifier
interventional
656
1 country
47
Brief Summary
The purpose of the study is to determine the usefulness of microvolt T wave alternans (MTWA) testing of patients that have had a heart attack and have decreased pumping ability of the lower chamber of their heart. MTWA testing is a non-invasive test used to detect the likelihood of developing abnormally fast rhythms in the lower chambers of the heart. The objective of the study is to prove that if a patient has a negative MTWA test, they will be less likely to develop abnormally fast and dangerous rhythms in the lower chambers of the heart. The results of the study will help doctors to determine which patients would benefit the most from having an Implantable Cardioverter Defibrillator (ICD) implanted.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2003
Longer than P75 for not_applicable
47 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2003
CompletedFirst Submitted
Initial submission to the registry
March 20, 2006
CompletedFirst Posted
Study publicly available on registry
March 21, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2007
CompletedFebruary 13, 2008
February 1, 2008
3.3 years
March 20, 2006
February 11, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Demonstrate that the life-threatening ventricular tachyarrhythmic event-free survival probability is greater in patients with a baseline MTWA Negative result as compared to patients with a baseline MTWA Non-Negative (Positive or Indeterminate) result.
Secondary Outcomes (3)
Compare occurrence of all ventricular events between both groups
Identify predictors of life threatening ventricular arrhythmias
Calculate occurrence of life threatening ventricular arrhythmias based on last MTWA results
Interventions
Eligibility Criteria
You may qualify if:
- Patients indicated for an ICD with a history of heart attacks
- LVEF \<= 0.30 as measured by a radionuclide study, angiography or quantitative echocardiography within 3 months prior to enrollment
You may not qualify if:
- Patients with electrocardiographically documented sustained ventricular tachycardia, ventricular fibrillation or prior cardiac arrest (Class I indications)
- Patients who have undergone an electrophysiologic study with ventricular stimulation or a MTWA test within 1 year prior to enrollment
- Patients with medical conditions that preclude the testing required by the Investigational Plan or limit study participation
- Patients unable to complete MTWA testing requirements due to current atrial fibrillation or flutter
- Patients unable to exercise and for which alternative modalities (pacing or pharmacological stress) used for MTWA testing are not available
- Patients who have experienced an MI within 1 month prior to enrollment
- Patients with advanced cerebrovascular disease per physician's assessment
- Patients classified as NYHA Class IV at time of enrollment
- Patients who have undergone cardiac revascularization within 3 months prior to enrollment or are scheduled for cardiac revascularization at the time of enrollment
- Patients with a life expectancy of less than 1 year
- Patients with prior ICD
- Patients unable to complete follow-up visits at the study center
- Patients who are enrolled or intend to participate in another clinical study that would compete with the study objectives (assessment will be the responsibility of the Clinical Trial Leader with guidance from the Executive Committee)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medtronic Cardiac Rhythm and Heart Failurelead
- Medtroniccollaborator
Study Sites (47)
Unknown Facility
Mobile, Alabama, United States
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Walnut Creek, California, United States
Unknown Facility
Denver, Colorado, United States
Unknown Facility
Hartford, Connecticut, United States
Unknown Facility
Hollywood, Florida, United States
Unknown Facility
Naples, Florida, United States
Unknown Facility
Safety Harbor, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Joliet, Illinois, United States
Unknown Facility
Springfield, Illinois, United States
Unknown Facility
Beech Grove, Indiana, United States
Unknown Facility
Kansas City, Kansas, United States
Unknown Facility
New Orleans, Louisiana, United States
Unknown Facility
Hyannis, Massachusetts, United States
Unknown Facility
Grand Rapids, Michigan, United States
Unknown Facility
Saginaw, Michigan, United States
Unknown Facility
Saint Joseph, Michigan, United States
Unknown Facility
Minneapolis, Minnesota, United States
Unknown Facility
Omaha, Nebraska, United States
Unknown Facility
Las Vegas, Nevada, United States
Unknown Facility
East Islip, New York, United States
Unknown Facility
Flushing, New York, United States
Unknown Facility
West Islip, New York, United States
Unknown Facility
Gastonia, North Carolina, United States
Unknown Facility
Greensboro, North Carolina, United States
Unknown Facility
High Point, North Carolina, United States
Unknown Facility
Raleigh, North Carolina, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Cleveland, Ohio, United States
Unknown Facility
Columbus, Ohio, United States
Unknown Facility
Toledo, Ohio, United States
Unknown Facility
Doylestown, Pennsylvania, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Scranton, Pennsylvania, United States
Unknown Facility
Spartanburg, South Carolina, United States
Unknown Facility
Chattanooga, Tennessee, United States
Unknown Facility
Germantown, Tennessee, United States
Unknown Facility
Amarillo, Texas, United States
Unknown Facility
Corpus Christi, Texas, United States
Unknown Facility
Plano, Texas, United States
Unknown Facility
Tyler, Texas, United States
Unknown Facility
Burlington, Vermont, United States
Unknown Facility
Chesapeake, Virginia, United States
Unknown Facility
Portsmouth, Virginia, United States
Unknown Facility
Appleton, Wisconsin, United States
Related Publications (1)
Chow T, Kereiakes DJ, Onufer J, Woelfel A, Gursoy S, Peterson BJ, Brown ML, Pu W, Benditt DG; MASTER Trial Investigators. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol. 2008 Nov 11;52(20):1607-15. doi: 10.1016/j.jacc.2008.08.018.
PMID: 18992649DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
David G. Benditt, MD
University of Minnesota
- STUDY CHAIR
Theodore Chow, MD
The Lindner Center for Research and Education
- STUDY CHAIR
Dean J Kereiakes, MD, FACC
The Lindner Center for Research and Education
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
March 20, 2006
First Posted
March 21, 2006
Study Start
October 1, 2003
Primary Completion
February 1, 2007
Study Completion
February 1, 2007
Last Updated
February 13, 2008
Record last verified: 2008-02